Literature DB >> 10545643

Steroid treatment improves cochlear function in the MRL.MpJ-Fas(lpr) autoimmune mouse.

D R Trune1, R J Wobig, J B Kempton, S H Hefeneider.   

Abstract

Corticosteroid therapy is used to reverse autoimmune sensorineural hearing loss, although little is known of the mechanism by which this occurs. This has been due to the lack of a suitable animal model with spontaneous hearing loss that is steroid responsive. The present study examined the effects of prednisolone treatment on auditory thresholds in the MRL.MpJ-Fas(lpr) autoimmune mouse to determine its suitability as such a model. Autoimmune mice at 3.5-4. 5 months of age were evaluated by pure-tone auditory brainstem response (ABR) to establish threshold elevations due to the disease. The steroid treatment group was then given prednisolone in their drinking water for 2.5 months, while untreated controls were given tap water. Significantly more steroid treated mice survived to the time of post-treatment ABR evaluation. Half of the steroid treated ears demonstrated either improvement or no change in cochlear function compared to only 25% in the untreated controls. Overall, cochlear thresholds in the untreated controls increased by 14.7 dB, whereas no significant threshold increase was seen in the steroid treated group (4.3 dB) over the treatment period. No qualitative anatomical differences were seen in the ears of those mice surviving to the end of the study. These findings establish the autoimmune mouse as a model for studies of steroid responsive mechanisms within the ear. This could apply to autoimmune sensorineural hearing loss, as well as any hearing disorder for which steroid therapy is recommended.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10545643     DOI: 10.1016/s0378-5955(99)00147-1

Source DB:  PubMed          Journal:  Hear Res        ISSN: 0378-5955            Impact factor:   3.208


  9 in total

1.  Therapy of hearing disorders - conservative procedures.

Authors:  Stefan Plontke
Journal:  GMS Curr Top Otorhinolaryngol Head Neck Surg       Date:  2005-09-28

Review 2.  Immunosuppressive therapy for autoimmune inner ear disease.

Authors:  Maria C Buniel; Katie Geelan-Hansen; Peter C Weber; Vincent K Tuohy
Journal:  Immunotherapy       Date:  2009-05       Impact factor: 4.196

3.  Combined Intratympanic and Systemic Steroid Therapy in Sudden Sensorineural Hearing Loss.

Authors:  Sukhdev Khadav; Pooja Arya; Gaurav Gupta; Deep Chand; Ramchander Bishnoi; Devendra Singh Chawra
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2020-08-25

Review 4.  Intratympanic steroids as primary initial treatment of idiopathic sudden sensorineural hearing loss. The Hospital Universitario Ramón y Cajal experience and review of the literature.

Authors:  Tomás Labatut; María José Daza; Antonio Alonso
Journal:  Eur Arch Otorhinolaryngol       Date:  2012-12-20       Impact factor: 2.503

5.  Blocking the glucocorticoid receptor with RU-486 does not prevent glucocorticoid control of autoimmune mouse hearing loss.

Authors:  Dennis R Trune; J Beth Kempton
Journal:  Audiol Neurootol       Date:  2009-11-16       Impact factor: 1.854

6.  A clinical analysis of sudden sensorineural hearing loss cases.

Authors:  Hyun Soo Lee; You Jae Lee; Bo Sung Kang; Byung Don Lee; Ji Sung Lee
Journal:  Korean J Audiol       Date:  2014-09-16

7.  Intratympanic dexamethasone injection vs methylprednisolone for the treatment of refractory sudden sensorineural hearing loss.

Authors:  Nezamoddin Berjis; Saeed Soheilipour; Alireza Musavi; Seyed Mostafa Hashemi
Journal:  Adv Biomed Res       Date:  2016-06-20

8.  Intratympanic steroid treatment for idiopathic sudden sensorineural hearing loss after failure of intravenous therapy.

Authors:  Emanuele Ferri; Antonio Frisina; Anna Chiara Fasson; Enrico Armato; Giacomo Spinato; Maurizio Amadori
Journal:  ISRN Otolaryngol       Date:  2012-02-19

9.  Intratympanic methylprednisolone as rescue therapy in sudden sensorineural hearing loss.

Authors:  Igor Teixeira Raymundo; Fayez Bahmad; Jairo Barros Filho; Thaís Gonçalves Pinheiro; Nilda Agostinho Maia; Carlos Augusto Oliveira
Journal:  Braz J Otorhinolaryngol       Date:  2010 Jul-Aug
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.